Amann Philipp M, Susic Marijan, Glüder Franziska, Berger Hans, Krapf Wolfgang, Löffler Harald
Department of Dermatology, SLK Hospital Heilbronn, DE- 74078 Heilbronn, Germany.
Acta Derm Venereol. 2015 Mar;95(3):329-31. doi: 10.2340/00015555-1928.
Pityriasis rubra pilaris (PRP) is an uncommon cutaneous disease with disorder of keratinisation. Up to now, systemic retinoids like acitretin or isotretinoin seem to be the most effective therapeutic agents. However, no large trials on this rare disease have been published and no standardised treatment has been established so far. Recently, single case reports demonstrate beneficial effects of alitretinoin (9-cis retinoic acid) in patients with PRP. We performed a retrospective observational analysis of type I adult-onset patients with PRP (n = 5) treated with systemic alitretinoin in our department. Alitretinoin was highly effective in the treatment of PRP in 4 of 5 cases. PASI score was reduced significantly in the alitretinoin responders. We assume that alitretinoin could serve as an additional effective systemic treatment option for type I adult-onset PRP.
红皮病型毛发红糠疹（PRP）是一种罕见的、伴有角化异常的皮肤疾病。到目前为止，系统使用维甲酸类药物如阿维A或异维A酸似乎是最有效的治疗药物。然而，尚未有关于这种罕见疾病的大型试验发表，且目前尚未建立标准化的治疗方案。最近，单病例报告显示阿利维A酸（9-顺式维甲酸）对PRP患者有有益效果。我们对在我科接受系统阿利维A酸治疗的I型成人起病PRP患者（n = 5）进行了一项回顾性观察分析。阿利维A酸对5例患者中的4例治疗PRP非常有效。在阿利维A酸治疗有效的患者中，PASI评分显著降低。我们认为阿利维A酸可作为I型成人起病PRP的一种额外有效的系统治疗选择。
